Meloxicam
An NSAID that selectively inhibits COX-2 to reduce pain and inflammation from osteoarthritis, rheumatoid arthritis, and juvenile arthritis, with a somewhat lower risk of gastrointestinal side effects compared to non-selective NSAIDs. It is taken once daily due to its long half-life.
Molecular Weight
351.4000 g/mol
LogP
3.00
TPSA
136.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
2D Structure
Cite this structure
Embed this structure
SMILES
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
InChI
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
Molecular Formula
C14H13N3O4S2
HBD / HBA
2 / 7
Rotatable Bonds
2
Heavy Atoms
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An NSAID that selectively inhibits COX-2 to reduce pain and inflammation from osteoarthritis, rheumatoid arthritis, and juvenile arthritis, with a somewhat lower risk of gastrointestinal side effects compared to non-selective NSAIDs. It is taken once daily due to its long half-life.
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Yes, Meloxicam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL599. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54677470. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="meloxicam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/meloxicam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/meloxicam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/meloxicam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="meloxicam"></drugfyi-drug>